Monterey Bio Acquisition Corporation
MTRY · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.02 | -0.00 | 0.00 |
| FCF Yield | -3.33% | -0.66% | 0.00% |
| EV / EBITDA | -14.73 | -269.76 | 0.00 |
| Quality | |||
| ROIC | -10.33% | -0.44% | -0.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 1.61 | – |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -6.85% | 0.00% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.07 | 0.98 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |